These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 20497423

  • 1. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
    Wang BH, Bertucci MC, Ma JY, Adrahtas A, Cheung RY, Krum H.
    Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):912-8. PubMed ID: 20497423
    [Abstract] [Full Text] [Related]

  • 2. Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment.
    Horackova M, Schück O, Komers R, Charvat J, Teplan V, Kvapil M.
    Int J Clin Pharmacol Ther; 2005 Sep; 43(9):413-9. PubMed ID: 16163893
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
    Aw TJ, Liew D, Tofler GH, Schneider HG, Morel-Kopp MC, Billah B, Krum H.
    J Hypertens; 2006 Oct; 24(10):1979-84. PubMed ID: 16957557
    [Abstract] [Full Text] [Related]

  • 5. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
    Muscará MN, McKnight W, Asfaha S, Wallace JL.
    Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
    [Abstract] [Full Text] [Related]

  • 6. Effects of angiotensin III on protein, DNA, and collagen synthesis of neonatal cardiomyocytes and cardiac fibroblasts in vitro.
    Wang HX, Zhang QF, Zeng XJ, Wang W, Tang CS, Zhang LK.
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):393-402. PubMed ID: 20861513
    [Abstract] [Full Text] [Related]

  • 7. The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent.
    Hasinoff BB, Patel D, Wu X.
    Cardiovasc Toxicol; 2007 Dec; 7(1):19-27. PubMed ID: 17646679
    [Abstract] [Full Text] [Related]

  • 8. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ.
    Clin Cancer Res; 2005 Mar 01; 11(5):1999-2007. PubMed ID: 15756026
    [Abstract] [Full Text] [Related]

  • 9. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 01; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 10. [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
    Zhu FS, Chen XM, Wang YJ, Zhang X, Feng JX.
    Zhonghua Zhong Liu Za Zhi; 2007 Mar 01; 29(3):186-8. PubMed ID: 17649633
    [Abstract] [Full Text] [Related]

  • 11. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ, Wentworth C, Burke TA, Makuch RW.
    Pharmacoepidemiol Drug Saf; 2004 May 01; 13(5):277-87. PubMed ID: 15133778
    [Abstract] [Full Text] [Related]

  • 12. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 01; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 01; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 14. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG, Schencking M, Scheer C, Rupp H.
    Praxis (Bern 1994); 1997 Apr 02; 86(14):566-74. PubMed ID: 9198851
    [Abstract] [Full Text] [Related]

  • 15. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov 02; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 16. Dopamine D2 receptor stimulation inhibits angiotensin II-induced hypertrophy in cultured neonatal rat ventricular myocytes.
    Li H, Shi S, Sun YH, Zhao YJ, Li QF, Li HZ, Wang R, Xu CQ.
    Clin Exp Pharmacol Physiol; 2009 Mar 02; 36(3):312-8. PubMed ID: 18986329
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Lüscher TF, Ruschitzka F.
    Circulation; 2003 Nov 11; 108(19):2308-11. PubMed ID: 14597594
    [Abstract] [Full Text] [Related]

  • 18. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F, Michaud K, Burke TA, Zhao SZ.
    J Rheumatol; 2004 Feb 11; 31(2):355-8. PubMed ID: 14760808
    [Abstract] [Full Text] [Related]

  • 19. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
    Wu R, Laplante MA, de Champlain J.
    Hypertension; 2005 Jun 11; 45(6):1139-44. PubMed ID: 15851630
    [Abstract] [Full Text] [Related]

  • 20. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 11; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.